3,900 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by MBB Public Markets I LLC

MBB Public Markets I LLC bought a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,900 shares of the biotechnology company’s stock, valued at approximately $492,000.

A number of other hedge funds have also made changes to their positions in RGEN. Norden Group LLC increased its holdings in shares of Repligen by 1,711.6% in the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock valued at $7,137,000 after purchasing an additional 36,663 shares during the last quarter. Artemis Investment Management LLP grew its position in Repligen by 33.8% in the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after acquiring an additional 42,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the period. Congress Asset Management Co. MA grew its position in Repligen by 14.6% in the first quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after acquiring an additional 11,213 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Repligen by 21.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock worth $61,767,000 after buying an additional 59,903 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 2.1 %

NASDAQ:RGEN opened at $145.74 on Wednesday. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.16 billion, a PE ratio of 582.98, a price-to-earnings-growth ratio of 4.32 and a beta of 0.94. The stock has a fifty day moving average price of $149.18 and a 200 day moving average price of $152.84.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. During the same period last year, the firm earned $0.53 earnings per share. Repligen’s quarterly revenue was down 3.2% on a year-over-year basis. Sell-side analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on RGEN shares. UBS Group lowered their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, Guggenheim assumed coverage on Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.